Porgaviximab is a monoclonal antibody (IgG1 kappa) developed for the specific treatment and prevention of Ebola virus disease (EVD) caused by the Zaire ebolavirus species. Its therapeutic mechanism involves the precise targeting of the viral envelope glycoprotein (GP). By binding with high affinity to a critical epitope on this surface protein, the antibody effectively neutralizes the virus. This neutralization primarily works by blocking the interaction between the viral GP and its host cell receptors (such as Niemann-Pick C1), thereby preventing viral attachment, entry, and subsequent infection of human cells.